ZYLOX-TONBRDG.MED.TECH.H1 (818) — Tangible Net Worth Ratio
ZYLOX-TONBRDG.MED.TECH.H1 (818) has a Tangible Net Worth Ratio of 98.0% as of June 2025. This metric is calculated by deducting intangible assets (€63.34 Million) from net assets (€3.15 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See ZYLOX-TONBRDG.MED.TECH.H1 shareholders equity for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
ZYLOX-TONBRDG.MED.TECH.H1 Tangible Net Worth Ratio (2021–2024)
This chart shows how ZYLOX-TONBRDG.MED.TECH.H1's Tangible Net Worth Ratio has changed across 4 annual periods from 2021 to 2024. As of June 2025, the ratio stands at 98.0%, reflecting net assets of €3.15 Billion with intangible assets of €63.34 Million EUR. Also explore 818 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for ZYLOX-TONBRDG.MED.TECH.H1 (2021–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for ZYLOX-TONBRDG.MED.TECH.H1 from 2021 to 2024, covering 4 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see 818 market cap.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 98.0% | €3.10 Billion | €61.38 Million | €3.45 Billion | ▼ -0.5 pp |
| 2023 | 98.6% | €3.05 Billion | €43.79 Million | €3.38 Billion | ▲ +0.0 pp |
| 2022 | 98.6% | €3.09 Billion | €44.47 Million | €3.25 Billion | ▼ -0.5 pp |
| 2021 | 99.1% | €3.14 Billion | €29.72 Million | €3.25 Billion | — |